Baird analyst Michael Ha has increased the price target for Privia Health (PRVA, Financial) to $26, up from the previous $24, while maintaining an Outperform rating on the stock. This adjustment reflects positive expectations for the company's performance despite broader challenges in the healthcare sector.
Baird points out that there will likely be limited new buyers for stocks across the managed care and healthcare facilities sector until current policy uncertainties are resolved. The firm anticipates that companies will continue to adopt cautious financial guidance for 2025, partly due to potential pressures from Part D and broader economic challenges that may arise later in the year.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 21 analysts, the average target price for Privia Health Group Inc (PRVA, Financial) is $29.76 with a high estimate of $40.00 and a low estimate of $23.00. The average target implies an upside of 23.75% from the current price of $24.05. More detailed estimate data can be found on the Privia Health Group Inc (PRVA) Forecast page.
Based on the consensus recommendation from 23 brokerage firms, Privia Health Group Inc's (PRVA, Financial) average brokerage recommendation is currently 1.7, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Privia Health Group Inc (PRVA, Financial) in one year is $53.32, suggesting a upside of 121.7% from the current price of $24.05. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Privia Health Group Inc (PRVA) Summary page.
